Exhibit 10.1
AMENDMENT NO. 3 TO CREDIT AGREEMENT
This Amendment No. 3 to Credit Agreement (this “Amendment”) effective as of November 30, 2022 and executed on December 1, 2022, is among Baudax Bio, Inc., a Pennsylvania corporation (“Borrower”), Baudax Bio N.A. LLC, a Delaware limited liability company (“Baudax LLC”), Baudax Bio Limited, a private company incorporated under the laws of Ireland limited by shares having company number 562027 (together with Baudax LLC, collectively, the “Guarantors” and together with the Borrower, the “Loan Parties”), Wilmington Trust, National Association, not individually, but solely in its capacity as administrative and collateral agent for the Lenders (the “Agent”) and the Lenders party hereto.
WHEREAS, the Borrower, the Lenders and the Agent are party to that certain Credit Agreement, dated as of May 29, 2020, as amended by that certain Amendment No. 1 and Waiver to Credit Agreement, dated as of August 1, 2022 and that certain Amendment No. 2 to Credit Agreement, dated as of October 24, 2022 (collectively, the “Credit Agreement”), pursuant to which the Lenders agreed to make loans to the Borrower on the terms set forth therein;
WHEREAS, the Borrower has requested that the Agent and the Lenders make certain amendments to the Credit Agreement, and the Agent and the Lenders are willing to make such amendments to the Credit Agreement on the terms and subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Definitions: Loan Document. Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents.
2. Amendment. Upon the effectiveness of this Amendment, the Credit Agreement is hereby amended as follows:
(a) Section 7.17.1 is amended and restated in its entirety as follows:
“7.17.1 Liquidity Accounts. Not suffer or permit the aggregate amount of cash in the Liquidity Accounts (a) from October 1, 2022 to December 6, 2022 to be less than $3,000,000 at any time, (b) from December 7, 2022 to February 28, 2023 to be less than $4,500,000, and (c) from and after March 1, 2023 to be less than $4,000,000.”
3. Expenses. The Loan Parties agree to pay all out-of-pocket and documented costs and expenses of the Agent and the Lenders (including diligence costs, consulting fees and Costs) in connection with the transactions contemplated by this Agreement invoiced to the Borrower (including, without limitation, the reasonable and documented fees and out-of-pocket expenses of counsel to the Agent and the Lenders incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and the other Loan Documents). Without limitation of the foregoing, the Loan Parties agree to pay (a) on December 1, 2022 to the Agent’s counsel its outstanding fees in the aggregate amount of $6,705.00 and (b) on December 8, 2022 to the Lenders’ counsel its outstanding fees in the aggregate amount of $42,813.58.